A novel brain tumour model in zebrafish reveals 1 the role of YAP activation in 2 MAPK/PI3K induced malignant growth by Mayrhofer, Marie et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A novel brain tumour model in zebrafish reveals 1 the role of YAP
activation in 2 MAPK/PI3K induced malignant growth
Citation for published version:
Mayrhofer, M, Gourain, V, Reischl, M, Affaticati, P, Jenett, A, Joly, J-S, Benelli, M, Demichelis, F, Poliani,
PL, Sieger, D & Mione, M 2016, 'A novel brain tumour model in zebrafish reveals 1 the role of YAP
activation in 2 MAPK/PI3K induced malignant growth' Disease Models & Mechanisms. DOI:
10.1242/dmm.026500
Digital Object Identifier (DOI):
10.1242/dmm.026500
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Disease Models & Mechanisms
Publisher Rights Statement:
© 2016. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0This is an Open
Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any
medium provided that the original work is properly attributed.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
© 2016. Published by The Company of Biologists Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction 
in any medium provided that the original work is properly attributed. 
A novel brain tumour model in zebrafish reveals the role of YAP activation in 
MAPK/PI3K induced malignant growth. 
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 Summary statement 
A new brain tumour model in zebrafish allows simultaneous analysis of malignant tumours 
and heterotopias, suggesting that both lesions originate from similar events, with Yap1 as a 
driving force in tumour development. 
 
Abstract 
Somatic mutations activating MAPK/PI3K signalling play a pivotal role in both tumours and 
brain developmental disorders. We developed a zebrafish model of brain tumour based on 
somatic expression of oncogenes that activate MAPK/PI3K signalling in neural progenitor 
cells. HRASV12 was the most effective in inducing both heterotopia and invasive tumours. 
Tumours, but not heterotopias, require persistent activation of phospho-(p)ERK and express a 
gene signature similar to the mesenchymal glioblastoma subtype, with a strong YAP 
component. Application of a 8-gene signature to human brain tumours establishes that YAP 
activation distinguishes between mesenchymal glioblastoma and low grade glioma in a wide 
TCGA sample set including gliomas and glioblastomas (GBMs). This suggests that the 
activation of YAP may be an important event in brain tumour development, promoting 
malignant versus benign brain lesions. Indeed, co-expression of dominant active YAP 
(YAPS5A) and HRASV12 abolishes the development of heterotopias and leads to the sole 
development of aggressive tumours. Thus, we have developed a model proving that 
neurodevelopmental disorders and brain tumours may originate from the same somatic 
mutations activating oncogenes and established that YAP activation is a hallmark of malignant 
brain tumours.  
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 Introduction 
 
Disorders of brain growth are known to cause a wide range of physiological and pathological 
symptoms such as intractable epilepsy, intellectual disability, autism, cognitive and motor 
impairment (Aronica and Crino, 2014, Courchesne et al., 2001, Hevner, 2015). Their causes 
are diverse and comprise: (i) focal lesions characterised by abnormal location of otherwise 
normally differentiated neural cells (Thom et al., 2004), (ii) “tuberous” formation and similar 
disorders with abnormally large neurons and/or other cell types (Blumcke et al., 2011, Crino, 
2013) and (iii) brain overgrowth syndromes leading to diffuse megalencephaly or 
malformations (Winden et al., 2015), which are mostly limited to developmental stages. By 
contrast, paediatric and adult primary malignant brain tumours are characterised by the 
sustained proliferation of poorly differentiated or abnormal neural cells. Both types of 
diseases (brain growth disorders and tumours) may initially appear with similar symptoms 
and share a similar origin from somatic mutations (Blumcke et al., 2011), which is confirmed 
by co-occurrence of both disorders in the same patients (Johansson et al., 2015). For example, 
coexistence of developmental disorders and brain tumours is commonly observed in 
neurofibromatosis type 1 (Reuss and von Deimling, 2009) (NF1), a genetic disorder that 
afflicts 1 in about 3000 newborns (Evans et al., 2010). NF1 is caused by loss-of-function 
mutations in the tumour suppressor gene NF1, which encodes neurofibromin 1, a negative 
regulator of the proto-oncogene RAS (Ballester et al., 1990, Cichowski and Jacks, 2001) and 
in 50 % of cases occurs as the result of de novo somatic mutations. 5-10 % of patients with 
tuberous sclerosis (caused by mutations in TSC1 or TSC2, OMIN 191100) develop slowly 
growing subependymal giant cell astrocytomas (Grajkowska et al., 2010) and in 50 % of 
patients with focal cortical dysplasia type 3b cortical disorganisation masks slowly-
developing brain tumours (Blumcke et al., 2011, Palmini et al., 2013, Santos et al., 2014). 
However, for most developmental disorders of the brain it is currently unknown whether focal 
or diffuse growth disorders may progress to tumours due to additional mutations or epigenetic 
events. Although the molecular pathogenesis of these disorders are currently unknown, for 
most of them genetic studies show that activation of MAPK/PI3K or mTOR signals due to de 
novo somatic mutations or inherited germline mutations may be causative (for review see 
(Aronica and Crino, 2014, Barkovich et al., 2012, Dyment et al., 2013, Hevner, 2015). These 
pathways are also altered in gliomas, as leading mutations in high grade gliomas include 
EGFR amplification (in 27-36 % of cases, (Ohgaki and Kleihues, 2007) or mutations (18-
31 % of cases, (Liu et al., 2005), deletion of PTEN, the inhibitor of AKT and mTOR (15-40 % 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
 of cases, (Tohma et al., 1998) and inactivation of NF1, a RAS inhibitor (18 % of cases, TCGA 
(Network, 2008). While only few gliomas contain mutation in RAS itself, the leading 
mutations reported above affect its activity in nearly all glioma cases (Jones et al., 2012, Patil 
et al., 2013). On the other hand, activation of Ras/Raf is the molecular hallmark of pilocytic 
astrocytoma (a grade I astrocytoma, which rarely progresses to higher grade (Jones et al., 
2008). 
While separate models for developmental disorders or brain tumour diseases exist 
(Fomchenko and Holland, 2006, Stylli et al., 2015, Wong and Roper, 2015), models of 
progressive brain developmental disorders with spontaneous cancerous development are 
lacking. Such models may allow the study of the molecular events leading to tumour 
development starting from benign developmental lesions, the identification of the 
mechanisms of tumour suppression in those cases that do not progress and the development of 
preventive therapies. These models may also be instrumental in understanding the progression 
from benign to malignant brain tumours, such as glioblastoma (GBM), which occurs in ~50 % 
of patients diagnosed with grade II and grade III gliomas (Chaichana et al., 2010, Ho et al., 
2016, Louis et al., 2007).  
Glioma progression has been linked to a number of pathway alterations including 
EGFR/MAPK/PTEN and p53 signalling (Ohgaki and Kleihues, 2009). Additionally, the 
transcriptional co-activators YAP/TAZ of the Salvador-Warts-Hippo pathway have been 
linked to glioma progression and poor patient survival (Bhat et al., 2011, Orr et al., 2011). An 
increase of YAP/TAZ activity has been documented in high grade gliomas, while they are 
significantly less active in low grade gliomas (Orr et al., 2011). In cell culture experiments 
YAP/TAZ promote glioma cell proliferation, invasion and resistance to apoptosis (Bhat et al., 
2011, Orr et al., 2011). However, their impact on the progression of low grade gliomas is still 
poorly documented. 
In this study we have generated a zebrafish model of focal brain growth disorders through the 
expression of different oncogenes in neural cells during development. These focal growths are 
of two types: either they result in dislocation of neural cells (or duplication of neural 
structures) without further growth, malformations defined as “heterotopias” or in malignant 
brain tumours. Thus, this model provides novel insights into the relation between benign 
lesions and aggressive tumours as it shows: i) that RAS/MAPK signalling can induce both 
heterotopia (non-cancerous benign lesions) and aggressive brain tumours, ii) that aggressive 
tumours have a mesenchymal GBM signature, iii) that activation of YAP signalling 
distinguishes aggressive tumours from heterotopia and iv) that forcing the activation of YAP 
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 signalling at earlier stages promotes aggressive tumours at the expenses of heterotopia. These 
data indicate a central role for YAP activation in the progression of benign growth disorders to 
aggressive tumours and suggest the possibility of preventing it by specific inhibitors.  
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 Results 
 
Activation of the EGFR/RAS/ERK/AKT pathway through the zic4 enhancer induces brain 
tumour development. 
 
To generate a brain tumour model, we used the Gal4-UAS system to induce expression of 
different oncogenes under the UAS promoter in the driver line 
Et(zic4:GAL4TA4,UAS:mCherry)hmz5 (Distel et al., 2009), further on referred to as zic:Gal4. 
This line expresses the codon-optimised version of the transcription factor Gal4 under control 
of the zic4 enhancer in the proliferating domains of the developing central nervous system 
(Fig. S1A-C’) which is visualised through mCherry expression. Zic:Gal4 is also expressed in 
the adult brains (Fig. S1C, C’) as documented previously for the endogenous zic4 gene 
(Aruga, 2004, Grinberg and Millen, 2005). We used different UAS-driven oncogenes, some 
activating the EGFR/RAS/ERK/AKT pathway, already reported to generate neoplasia in the 
zebrafish brain (GFP-KRASV12 (Ju et al., 2015), AKT (Jung et al., 2013), others known as 
oncogenic in human brain (GFP-EGFR transcript variant III (vIII) (Liu et al., 2005), also represented 
by Xmrk, the oncogenic version of the EGFR in Xiphoporus, and BRAFE600 (Penman et al., 
2015) (see Table S1 for list and full names of constructs). All these oncogenes induced 
tumour formation (Fig. S2A-D, Table S2) and all but AKT induced ERK phosphorylation 
(Fig. S2E), with GFP-HRASV12 exhibiting the strongest effect. 
To analyse the effect of activated RAS on tumour development, we generated both germline 
and somatic UAS:GFP-HRASV12 expressing animals. To induce germline UAS:GFP-
HRASV12 expression (shortened in zic:RASgermline, Fig. 1A), we crossed the line zic:Gal4 to 
the line tg(UAS:eGFP-HRASv12)io006 (Santoriello et al., 2010) (further on referred to as 
UAS:RAS). To induce somatic GFP-HRASV12 expression (zic:RASsomatic, Fig. 1B), embryos 
of the line zic:Gal4 were injected at 1-cell stage with the plasmid UAS:GFP-HRASV12. F0 
embryos expressing the transgene were identified by GFP expression and used for further 
analysis. 
Both approaches induced early but different effects. The germline approach affected all zic4+ 
cells in the brain (Fig. 1C-D') and already at 3 dpf led to a constant increase in brain size of 
2.3 times (Fig. 1E) which was accompanied by a similar increase in the number of 
proliferating cells (91.6 ± 11.0, n=5, in zic:RAS versus 34.1 ± 6.2, n=5, in zic:Gal4 larvae) as 
determined through BrdU staining (2.7 fold, Fig. 1F). The somatic approach instead lead to 
random oncogene expression in the zic4+ cell population affecting single cells in different 
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 number and localisation (Fig. 1G-G''). Hence, it allowed for detailed time lapse analysis of the 
affected cells, which revealed their clonal expansion in larvae (Fig. 1H-H'''). Even though 
both approaches lead to tumour formation, the difference between them is mostly reflected in 
their survival with the germline approach enabling only 4 % ± 1.2 % to survive the first 
month while the somatic approach allows 36.9 % ± 5.9 % to survive (Fig. 1I). 
Therefore, germline expression of UAS:GFP-HRASV12 in the brain of developing zebrafish 
induces highly reproducible effects enabling the possible application of this model in 
screening approaches. The somatic expression of UAS:GFP-HRASV12 instead is ideal for 
single cell analysis as well as investigation of mechanisms of clonal expansion and 
oncogenesis up to later stages. 
 
Expression of the oncogene GFP-HRASV12 induces brain tumours and/or heterotopia 
 
Next, brains of juvenile and adult fish (1-14 months) were resected and whole brains imaged 
for bright field and fluorescence. The observations unravelled the development of abnormal 
brain structures which could be grouped into malformations with and (mostly) without GFP-
expression; Fig. 2A-C). Both types of malformations occurred with the germline and with the 
somatic approach and were often found in the same brain (Table S2) but never in control 
injected fish (data not shown). Specifically, the analysis of 134 brains of zic:RASsomatic fish 
revealed that 81.2 % of the brains developed GFP+ malformations, appearing most frequently 
in the telencephalon (62.4 %), in the IVth ventricle (33.1 %) and in the diencephalon 
(30.1 %). However, 50.4 % of the fish developed malformations, which were mostly GFP-
negative (i.e. with only a few GFP+ cells, which for brevity we call GFP-); both types of 
malformations could be present in the same brain (Fig. 2D). 3D reconstruction allowed 
analysis of the infiltrative nature of GFP-expressing lesions (Fig. 2E-F) while GFP- 
malformations appeared as sharply circumscribed structures without penetration into deeper 
layers (Fig. 2G, white arrow). Further, the 3D reconstruction allowed to predict that several 
clones contributed to the large GFP+ malformations, which we interpreted as 
cancerousgrowths based on the analysis reported in the next paragraphs (Fig. 2H). 
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 Specific immunohistochemical signatures establish that GFP-HRASV12 positive lesions are 
tumours and show persistent activation of MAPK/ERK signalling. 
 
The relation between developmental brain lesions and glioma has been the focus of a number 
of recent reports (Hevner, 2015, Marin-Valencia et al., 2014, Reuss and von Deimling, 2009), 
raising the question as to whether developmental brain growth disorders (including focal 
dysplasia and heterotopia (Aronica and Crino, 2014, Hevner, 2015) may be the result of 
halted oncogenic events taking place during development and/or provide a substrate for brain 
tumour development. In our model, the same oncogenes lead to two types of lesions, one 
resembling cancer and the other resembling heterotopia, thus providing an opportunity to 
study possible co-factors, that may induce benign developmental lesions instead of tumours. 
The different nature of these lesions was assessed through H&E staining by an expert 
neuropathologist (PLP), who also recognised peculiar features associated to tumours 
developing in the different areas of the brain, spanning from embryonal to more differentiated 
histopathological features, suggesting that these zebrafish brain tumours may resemble 
different histological subtypes of Central Nervous System tumours (Louis et al., 2016). To 
further clarify these differences and understand why in some instances the oncogene 
HRASV12 expressed in brain progenitor cells induced tumour development and in other cases 
produced only heterotopias, we investigated the expression of different markers by 
immunofluorescence: BrdU uptake for proliferation, GFAP for glial cells, S100β for 
progenitor cells, HU-C  for neurons and p-ERK for MAPK activity. 
The pattern of staining for these markers was disrupted in tumours and in heterotopias in 
different ways. Specifically, in the telencephalon, tumours (present in 62.4 % of the injected 
fish, "T" in Fig. 2B) appeared as diffusely infiltrating malignant masses (Fig. 3A-C) showing 
strong cellular heterogeneity (Fig. 3D) and a high proliferation index (Fig. 3E-F). Besides 
proliferation, we assessed p-ERK levels, number of HU-C+ and S100β+ cells and GFAP 
staining. A summary of the stainings present in GFP+ tumours arising in different brain 
regions is shown in Fig. 3 and Fig. S3.  
GFP negative (-) heterotopias (present in 50.4 % of the injected fish, Fig. 2C) were defined as 
ectopically localised groups of cells, lacking or with only a mild atypia and basically 
reproducing normal neural cell types but in the wrong location and/or in a larger number, 
reminiscent of a lack of maturation or migration and/or prolonged proliferation. They were 
easily visualised in the optic tectum (Fig. 3K-T), thanks to its layered structure, but also 
occurred in the telencephalon (Fig. S4A-A’) and in the cerebellum (Fig. S4B-B’). P-ERK 
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 staining in the heterotopias was absent (Fig. 3Q), while HU-C, GFAP (Fig. 3R-S) and S100β 
(Fig. 3T) were similar to those in the adjacent periventricular grey zone, from which the optic 
tectum heterotopias seem to originate. This suggested that normal developmental processes in 
these lesions were not subverted like in tumours, but just delayed or mis-localised. Most 
notably, UAS:GFP-HRASV12 expression (visualised through GFP fluorescence of the 
transgene) was barely detectable and no increase of ERK phosphorylation was detected in 
these lesions, suggesting that either the oncogene was switched off after initial expression, or 
that UAS:GFP-HRASV12-expressing cells, which may have initiated abnormal 
migration/proliferation in the heterotopia, were eliminated so that at the time of the analysis, 
heterotopias only represented scar-like lesions.  
In conclusion, the immunophenotype of these lesions revealed profound differences between 
heterotopias and tumours, despite their common origin from somatic expression of 
oncogenes. Inter-tumour variability was found (Fig. 3 and Fig. S3), associated to the different 
areas of origin of the tumours.  
 
Analysis of global RNA expression established that brain tumours resemble GBMs of the 
mesenchymal signature, with a strong YAP component. 
 
To establish whether the zebrafish brain tumours developing in our models resemble a 
specific human  molecular subtype, we performed transcriptome analysis by RNA sequencing 
(RNAseq) of 3 brains of zic:RASsomatic fish, which carried tumour lesions in the 
telencephalon, diencephalon and IVth ventricle (Fig. S5A) and compared them with tumour 
free, age matched brains. Using hierarchical clustering on normalised gene expression, the 
samples clustered in two different groups according to their status (control or tumour, 
Fig. S5B). We performed an analysis of differential gene expression using DESeq2 (Love et 
al., 2014), and found 4194 genes differentially expressed (DE) (adjusted p-value < 0.05) in 
brain tumour samples compared to controls. Of these, 2499 genes were upregulated and 
1695 genes were downregulated (Fig. S5C-D).  
Next, we evaluated whether the zebrafish brain tumours corresponded to a specific glioma 
subclass. Verhaak and colleagues identified 840 GBM markers useful to classify glioblastoma 
in four main subtypes (Verhaak et al., 2010). The same gene signature was later applied to 
low grade brain tumours (Guan et al., 2014) and to mouse models of brain tumours 
(Henriquez et al., 2013). We first identified the zebrafish orthologs (Smedley et al., 2015) of 
the 840 human genes used by Verhaak et al. (Verhaak et al., 2010). Due to the presence of 
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 paralogs in the zebrafish genome (Howe et al., 2013). This resulted in a list of 1135 unique 
zebrafish Ensembl gene identifiers, which represented 91.31 % of the 840 human GBM 
markers used by Verhaak et al. (Verhaak et al., 2010) (Table S3). The 4 GBM subtypes were 
represented by similar numbers of orthologs in zebrafish (Fig. S5E). Using normalised 
expression data for the zebrafish orthologs of the human markers, we were able to classify the 
zebrafish brain tumours in one of the 4 GBM subtypes (Fig 4A). Moreover, to further 
investigate the molecular features of our model, a Gene Set Enrichment Analysis (GSEA) was 
performed with the whole ranked list of significantly DE genes. Using this enrichment 
method, the mesenchymal subtype was the only significantly over-represented GBM subclass. 
We found 82 upregulated zebrafish genes with a normalised enrichment score (NES) of 2.12 
and a nominal p-value < 0.001, compared to the classical subclass (up=38, NES=1.16), the 
proneural subclass (down=38, NES=-0.59) and the neural subclass (down=16, NES=-1.51) 
(Fig. 4B, Table S3). Interestingly, among the 82 zebrafish orthologs of mesenchymal GBM 
markers found significantly upregulated in our model, 5 genes were related to YAP 
signalling: YAP1, WWTR1, TGFBR2, ITGB2 and IQGAP1 (Table S3). This observation 
prompted us to look at YAP related genes in the total list of 4194 DE genes. To do this, we 
first created a refined list of 39 zebrafish orthologs of human genes related to YAP signalling, 
based on literature (Anakk et al., 2013, Kodaka and Hata, 2015, Lim et al., 2014, Mo et al., 
2014, Piccolo et al., 2014). Of them, 23 are significantly differentially expressed in the 
zebrafish brain tumours (adjusted p-value < 0.05, Table S4) which confirmed the 
mesenchymal nature of our tumour model as YAP/TAZ signalling has been shown to be 
highly related to the mesenchymal subtype of GBM (Bhat et al., 2011, Orr et al., 2011).  
To further investigate the importance of the role of mesenchymal markers, and in particular 
YAP, we used Qiagen© Ingenuity Pathway Analysis (IPA) which allowed us to identify 
possible upstream regulators, pathways involved and networks established by the DE genes in 
the zebrafish tumour model. 
Of the 33737 uploaded Ensembl zebrafish IDs, IPA mapped 11896 to human IDs (21841 left 
unmapped). IPA was able to assess the nature of the model based on the DE genes by 
returning “Cancer/Neoplasia” as the most prominent Disease/Function in the dataset 
(Fig. S6A). Additionally, among the deregulated pathways, IPA identified cancer related ones 
such as Gαq-Signalling, ERK/MAPK-Signalling, PI3K/Akt-Signalling and Hippo-Signalling 
(Fig. S6B, Table S5). Further, IPA ranks HRAS among the 15 most significant upstream 
regulators with a p-value of 3.03e-18. To understand which signalling molecules are 
responsible for the biological effects in our model, we performed a "Regulator Effects 
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 Network" analysis. In this analysis, IPA connects upstream regulators via their target genes to 
known phenotypic and functional downstream effects. The generated networks are then 
ranked by the consistency score that is directly proportional to the number of consistent and 
inconsistent paths and indirectly proportional to the network size. The “Regulatory Effects 
Network” with by far the highest consistency score is shown in Fig. S6C. This network 
contains 6 regulators; of those, YAP had the highest interconnectivity, i.e. the highest number 
of relationships with other genes. Moreover, YAP is the only of the 6 regulators that has a 
high p-score in the IPA network analysis (Table S6). In this analysis the network headed by 
HRAS ranked first, whereas the YAP network ranked 12. Finally, the two networks (HRAS 
and YAP) are highly connected, as shown in Fig. 4C. 
All together, these results suggest that YAP is an important regulator in this tumour model 
and indicate that tumours developing in this model have a mesenchymal gene signature, 
associated in humans with the most aggressive malignant glioma subtype. A YAP network 
based on the Ingenuity Pathway Knowledge Database, integrating our RNAseq expression 
data, is shown in Fig. S6D. 
 
YAP signalling is absent in heterotopia and expression of active YAP promotes 
development of aggressive brain tumours 
 
After showing the activation of YAP signalling in our model we next investigated the role of 
YAP activation on tumour formation in this model. To determine the activity of YAP in 
UAS:GFP-HRASV12 induced tumours we detected the expression levels of YAP through 
western blot analysis and found a strong increase in total YAP expression in tumours 
compared to controls and brains with heterotopia (Fig. 5A). Further, we found an increase in 
YAP target gene expression using qPCR on 22 genes. These data compared well to the NGS 
data on the same genes, of which 50 % (11 genes) were similarly upregulated, 9 % (2) were 
strongly upregulated and 41 % (9) were not significantly altered (Figure S7A-B). We chose 
the 8 most differentially expressed genes (yap, ccnd1, ctgfa, iqgap1, tgfb1a, tgfbr2, amot, 
itgb2) and tested this signature on different tumour types and heterotopia which showed 
overexpression of all 8 genes in tumours  of the IVth ventricle and of 6 genes in telencephalic 
tumours, but no overexpression in heterotopia (Fig. 5B-D). This suggests that Yap target gene 
expression differentiates tumours versus heterotopia and that some YAP targets (ctgfa and 
itgb2) may be tissue or tumour specific. 
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 To further confirm that the 8-gene YAP signature may be a useful molecular diagnostic tool, 
we analysed human tumours RNA.seq data of 166 GBM and 530 Brain Lower Grade Glioma 
(LGG) generated by the The Cancer Genome Atlas (TCGA) Research Network 
(http://cancergenome.nih.gov/). Unsupervised hierarchical clustering (Fig. 5E) demonstrates 
highly significant segregation of GBMs and LGGs (p < 10-45, OR = 28, Fisher Exact Test) 
supporting that YAP activation is a hallmark of malignant brain cancer and suggesting that 
this 8-gene signature may provide sufficient information to distinguish high grade from low 
grade gliomas. 
Further, the effect of YAP activation in UAS:GFP-HRASV12 induced tumours was 
investigated through expression of dominant active YAP (YAPS5A) under control of the UAS 
promoter. Somatic expression of UAS:YAPS5A alone (zic:YAPsomatic) induced development of 
brain tumours (Fig. S8A, B) with YAP target gene expression (Fig. S8C), mixed cell 
populations (Fig. S8D) and reduced survival comparable to zic:RASsomatic (Fig. S8E). Instead, 
somatic coexpression of UAS:GFP-HRASV12 and UAS:YAPS5A (zic:RAS,YAPsomatic, Fig. 6A) 
promoted tumour development earlier than in zic:RASsomatic (2 weeks, data not shown), and 
increased proliferation at 3 dpf and 14 dpf (Fig. 6B, C) compared to zic:RASsomatic larvae. 
Somatic coexpression of both oncogenes was nearly incompatible with survival allowing only 
4 % ± 2.7 % to survive the first month (Fig. 6D). Instead, the few survivors revealed a 
remarkable increase in the number of fish developing tumours up to 100% and a sharp drop in 
heterotopia formation down to only 10 % (Fig. 6E). Additionally, UAS:YAPS5A promoted 
aggressiveness of the developing tumours as they were characterised by strong proliferation 
and fast dedifferentiation as determined by strong staining for GFAP and nearly complete 
lack of HU-C staining (Fig. 6F).  
Thus, YAP activation is not only co-operating with UAS:GFP-HRASV12 in promoting tumour 
development but may also function to overcome mechanisms halting tumour development 
when oncogenes are accidentally expressed in somatic cells during brain development. 
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 Discussion 
 
The progression of pre-malignant developmental lesions to tumours has been proved for 
several tissues such as colon (Macrae et al., 2009) and pancreas (Aguirre et al., 2003). In the 
brain, the relation between focal brain developmental disorders and brain cancer has been the 
subject of several studies aiming at establishing whether a common genetic and 
developmental origin for these disorders exists in those cases with clear evidences of 
progression (Aronica and Crino, 2014, Guerrini and Dobyns, 2014, Hevner, 2015). However, 
for the majority of brain tumours, evidence of a developmental origin of the somatic 
mutations driving cancer is difficult to obtain. In this study, we have generated a model of 
progressive brain tumour where the same genetic drivers can give rise to cancer and 
heterotopia, and identified the signalling pathway that, once activated, promotes tumour 
development at the expenses of heterotopia. Our model suggests that somatic embryonic 
mutations activating MAPK/ERK signalling can drive both malformation of brain 
development and brain tumours, providing that upregulation of YAP signalling is necessary 
for tumour development. 
Somatic mutations in pro-oncogenic factors occurring during development start to be 
recognised as an important determinant of congenital brain malformation and 
neurodevelopmental disorders spanning from Proteous syndrome to Neurofibromatosis type I 
(reviewed in (Poduri et al., 2013). On the other hand, somatic pro-oncogenic mutations 
occurring in post-developmental stages are often associated with cancer. Several studies have 
suggested a possible progression between neuro-developmental lesions and brain cancer, 
especially when the activating mutations induce MAPK/ERK signalling (Hevner, 2015). If a 
progression is possible from non-cancerous neuro-developmental lesions caused by activating 
mutations in a pro-oncogenic pathway and brain cancer, then an important question is to 
identify the mechanisms which restrain affected cells from developing cancer during 
development, and lead to re-activation of a dormant oncogenic program in case of progression 
to cancer. However, until now no animal model has been described to allow the investigation 
of the link between heterotopia and tumour formation. 
In our study we have used different oncogenes to generate a model of brain growth disorders 
in zebrafish. This model shows that RAS/MAPK signalling can simultaneously induce both 
heterotopia and aggressive brain tumours and that the persistence of the signal differentiates 
brain tumours from benign developmental lesions. The reduction or absence of GFP-HRASV12 
expression in the heterotopia suggests that this could be due to the cells expressing UAS:GFP-
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 HRASV12 turning off activated Ras after initial expression or undergoing cell death after 
influencing the ectopic migration of their neighbouring cells. Further studies are needed to 
clarify this point. In the second part of our study we scrutinised the transcriptional programs 
activated in those lesions that progress to cancer. We focused on the factors, which appear to 
be responsible for maintaining ERK signalling in some neural cells, which will form tumours, 
or shut it down in others, which will develop benign heterotopias. We found that the gene 
expression profile of RAS/MAPK tumours resembles the mesenchymal GBM signature, 
reported by Verhaak et al. (Verhaak et al., 2010), which underlines their comparability to the 
human disease. Additionally, the zebrafish brain tumours expressed a strong YAP component. 
Yap1 (or YAP) is a transcription co-factor, shut off by the hippo pathway which controls organ 
size during development (reviewed in Meng et al., 2016). YAP is part of a classic 
phosphorylation cascade and is activated through different mechanisms to promote growth 
and migration in cancer (reviewed in (Yu et al., 2015)).  
For example pancreatic adenocarcinoma was shown to have a strong YAP component, as 
KRAS induced acinar-to-ductal metaplasia depends on YAP expression for progression to 
malignant ductal adenocarcinoma (Zhang et al., 2014). Moreover, cancer cells can use YAP to 
compensate for loss of mutant KRAS as shown in cell lines and mouse models of pancreatic 
cancer (Kapoor et al., 2014, Shao et al., 2014). In high grade gliomas, YAP has been shown to 
be activated especially in aggressive tumour types and its expression tends to correlate with 
low survival rates (Bhat et al., 2011, Orr et al., 2011). However, the molecular mechanisms 
behind this correlation are unknown. Analysis of medulloblastoma suggests that upstream 
regulators of the Hippo pathway control the activation of YAP in brain cancer. Indeed, 
inhibition of NF2 (encoded by MERLIN) induces nuclear localisation and activation of YAP, 
that can be rescued by YAP inhibition (Piccolo et al., 2014). Interestingly, the inheritable brain 
dysplasia Van Maldergen syndrome (VMS; MIM601390) is due to mutations of the Hippo 
upstream regulators Dchs1 and Fat4, and the phenotype in relevant mouse models can be 
rescued by YAP inhibition (Cappello et al., 2013).  
YAP activity can also be regulated through other mechanisms including interaction with 
cellular compartments such as the actin cytoskeleton. The actin cytoskeleton has been shown 
to be crucial for YAP nuclear localisation (Shao et al., 2014), sometimes in cooperation, but 
more often independently, of the Hippo pathway (Aragona et al., 2013). F-actin translates the 
mechanical signals from the extra cellular matrix to the cell. As a component of the tumour 
microenvironment, the extra cellular matrix has a significant impact on the development, 
progression, and therapy response in tumours (Giussani et al., 2015, Lu et al., 2012). F-actin 
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 can relay its effect on YAP through several mechanisms such as G-protein coupled receptors 
(GPCRs), which are known to combine the actin cytoskeleton with several signalling 
pathways (reviewed in (Regue et al., 2013), or IQGAP1, a scaffold protein known to regulate 
the F-actin and microtubule network and shown to play a pivotal role in a bile acid induced 
liver cancer through YAP (Anakk et al., 2013). Thus, YAP activation not only correlates with 
increased proliferation but may promote tumour progression through interactions with the 
tumour environment. However, the specific mechanism through which YAP translates 
physical inputs into cancer promoting signals is still to be elucidated. 
Our study shows an additional role of YAP in tumour development as expression of dominant 
active YAP demonstrates its co-operation with oncogenic RAS in the induction of brain 
cancer instead of neuro-developmental lesions. The mechanisms through which oncogenic 
RAS induces YAP activation only in some lesions and after some time (3 weeks) from its 
initial expression, are currently unknown, but may involve a downregulation of members of 
the ubiquitin ligase complex that target YAP for degradation (SOCS5/6(Hong et al., 2014)), or 
F-actin through GPCRs or IQGAP1. Further studies will clarify this point. 
In contrast to currently available rodent models on brain dysplasia or brain tumours, this 
zebrafish glioma model provides the advantage of simultaneous development of tumours and 
heterotopia in a nearly equal ratio, induced by the same oncogene, which enables the analysis 
of the mechanisms that control the decision in fate and the requirements for progression. 
Moreover, the model enables time dependent investigation of tumour progression in a living 
vertebrate on a single cell level. While development of brain tumours was also investigated in 
other zebrafish models (Ju et al., 2015, Ju et al., 2014, Solin et al., 2015), the model described 
here provides the advantage of highly frequent development of both heterotopias and 
neoplastic malignant lesions in more than 80 % of the specimens and very early onset of 
oncogenic processes, which not only shortens observation times but also allows for efficient 
screening of therapeutic agents, using prevention of tumour development and tumour 
progression as read-outs. Further analysis of the model developed in this study can provide an 
understanding of the mechanisms that promote the progression of benign lesions to malignant 
tumours and a convenient assay for testing inhibitory treatments that could prevent malignant 
transformation of developmental brain lesions.  
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 Materials and Methods 
 
Animal housing and line generation 
All fish lines were raised and maintained under standard conditions (Westerfield, 2000). Fish 
with mosaic somatic plasmid expression were generated by co-injection of 0.25 ng/µl DNA 
(see Table S1) and 0.25 ng/µl mRNA encoding Tol2 transposase into the cell of one-cell-
stage embryos. Embryos were kept at 28.5 °C in E3 solution and 0.003 % PTU (1-phenyl-2-
thiourea, Sigma Aldrich, Germany) was added to the media at 24 hpf to reduce pigmentation. 
For line generation, carriers were selected by fluorescence and outcrossed to wildtype strains 
as adults to generate F0. At least two different F0 per line were analysed, to identify potential 
insertion effects. No differences between alleles of the same transgenic lines were found, 
therefore we selected only one of them for further studies. 
All Animal experiments were carried out under EU regulations for animal experimentation. 
The project was approved by the Government of Baden-Württemberg, Regierungspräsidium 
Karlsruhe, Germany under Aktenzeichen 35-9185.81/G-41/14. 
 
Survival curve 
For survival analysis fish were housed in groups of ≤30 and survivors were counted at 0 dpf, 
6 dpf, 13 dpf, 24 dpf and 30 dpf. In this and all other comparative analyses, zic:Gal4 
fishes/brains were used as controls. The length of these intervals was decided after pilot 
observations that showed that the majority of the zic:RAS larvae died at around 10-12 dpf. 
For each curve at least 3 repeats were performed. The total numbers of animals used for the 
survival curve was 105 (zic:Gal4), 255 (zic:RASgermline), 166 (zic:RASsomatic), 100 
(zic:RAS,YAPsomatic).  
 
Live imaging of larvae 
For live imaging, larvae were anaesthetised with 0.02 % tricaine methanesulfonate (tricaine, 
Sigma Aldrich, Germany) in E3, embedded in 1 % low melting point (LM) agarose in E3 and 
imaged with a stereo microscope (LEICA MZTL III), LEICA DFC42 digital camera, LAS 
V4.5 software or with a confocal microscope (LEICA DMI 4000B) and LAS X software 
(Leica microsystems, Germany). For repeated imaging, larvae were removed from agarose 
after each imaging, and housed in 24 well plates as single larvae in E3 mixed with PTU at 
28.5 °C until next imaging session. 
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 Brain size quantification 
At 3 dpf zic:Gal4 (n = 12) and zic:RASgermline (n = 16) larvae were anesthetised with 0.02 % 
tricaine in E3, embedded in 1 % LM agarose in E3 and the whole brain imaged from dorsal to 
ventral using confocal (Leica DMI4000B, Leica microsystems, Germany) under the following 
settings: objective ACS APO 10.0x0.30 DRY; zoom 1.0 ; z-slice 2 µm; resolution 512x512. 
Using Matlab each stack of images was assigned a manual threshold and a manual region of 
interest covering the rostral brain until mid-brain boundary. Using a manual threshold, the 
RGB images were binarised, followed by a dilation (r = 5), hole filling, erosion (r = 5) and 
opening (r = 10). The extracted images were cropped using a binary region of interest. The 
resulting images were used to build a 3D-structure and the volume was quantified (= number 
of voxels*volume per voxel).  
 
BrdU, H&E, Immunostaining 
Fish were killed by anaesthetic overdose (0.04 % tricaine) and brains dissected under a 
stereomicroscope. All samples were fixed in 4 % PFA for 24 h before paraffin embedding. 
For proliferation analysis fish were incubated in 10 µM Bromo-deoxy-Uridin (BrdU, Sigma 
Aldrich, Germany) in E3 24 h prior to sample collection. In 10 larvae per group, total number 
of BrdU+ cells were counted in coronal sections of the telencephalic areas; in adults BrdU+ 
cells in tumours, heterotopias or in similar regions of control brains were counted in 2-3 
sections of 5 different samples (referring to an area of 0.5 mm2) given as fraction of total cell 
number (DAPI+ cells) in that field. 
For histological analysis 10 µm serial sections were stained with haematoxylin and eosin 
(H&E). Images were acquired using a light microscope (Zeiss Axioscope), AxioCam HRc 
camera and AxioVision SE64 Rel. 4.9.1 software. 
For immunohistochemic analysis sections were demasked with a citrate buffer antigen 
retrieval protocol(Brown and Chirala, 1995) and stained with primary antibodies against glial 
fibrillary acid protein (GFAP, 1:1000, DAKO, Germany, Z0334), S100β (S100β, 1:1000, 
DAKO, Germany, Z0311), HU-C (HU-C, 1:200, Life technologies, USA, A21271), phospho-
ERK (P-ERK, 1:200, Cell Signalling, USA, 9101S), green fluorescent protein (GFP, mouse 
1:500, Millipore, Germany, MAB3580 or rabbit 1:1000, Life technologies, USA, A11122). 
For staining with the antibody against BrdU (1:500, Cell Signalling, USA, 5292S) sections 
were additionally treated for 20 min with 2 N HCl. All sections were stained with fluorescent 
labelled secondary antibodies against rabbit or mouse immunoglobulins (1:200, Life 
technologies, USA, A11017, A11018, A11070, A11071, A21050, A21070). Images were 
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 acquired using a confocal microscope (LEICA DMI 4000B) and LAS X software (Leica 
microsystems, Germany). 
To obtain the summaries of immunostainings shown in figure 3E/O at least 5 different 
tumours per region or heterotopias were examined. Number of positive cells or percentage of 
positive area was evaluated in an area of approximately 0.5 mm2 in 3 different sections per 
tumour/heterotopia. The symbols are representative of these counts: less than 5 % positive 
cells/area = +/-; between 5 and 25 % = +; between 25 and 50 % = ++; over 50 % = +++.  
 
RNA-analysis 
All fish were killed by anaesthetic overdose (0.04 % tricaine) and brains of juveniles and 
adults dissected under a stereomicroscope. Larvae and tissue samples for RNA extraction 
were collected and lysed in trizol (life technologies, USA) and total RNA extracted with the 
RNeasy Mini Kit (Qiagen, Germany) following manufacturers protocol. Samples for 
quantitative PCR (qPCR) analysis were additionally treated with RNA-Free DNase (Quiagen, 
Germany) for 30 min at RT. 
For gene expression analysis via qPCR RNA samples were transcribed to cDNA applying the 
SuperScript® ViloTM cDNA Synthesis Kit (invitrogen, USA) and qPCR was performed using 
the Gotaq® qPCR Master Mix (Promega, Germany) following manufacturer’s protocol in the 
StepOnePlus Real-Time PCR System (Applied Biosystems, Germany), with the following 
setting: 95 °C, 15 min; 40x (95 °C, 15 sec; 60 °C, 30 sec); 95 °C, 15 sec; 60 °C, 1 min; 
melting curve 0.5 °C per 15 sec to 95 °C. Data were analysed with the StepOne Software 
v2.3. For normal PCR cDNA samples were diluted 1:10 and 10 µl added to PCR mix (10.5 µl 
dH2O, 1 µl dNTPs (10 mM mix), 1 µl primer each, 0.5 µl GoTaq® (Promega, Germany), 8 µl 
5xbuffer (provided by GoTaq® kit) and amplified in the T100TM Thermal Cycler (BioRad, 
USA) (95 °C, 5 min; 27x (95 °C, 30 sec; 60 °C, 30 sec; 72 °C, 30 sec) 72 °C, 5 min; 12 °C, 
∞). Primer pairs are listed in Table S8.  
For next generation sequencing (NGS), the quality of the extracted total RNA samples, using 
the RNeasy Mini Kit (Qiagen, Germany), was assessed on RNA nanochips (Bioanalyser 2100 
Agilent, USA). The libraries were prepared from 1 µg RNA using the Illumina TrueSeq 
mRNA kit (Illumina, USA) according to the suppliers protocol. The size and the 
concentration of the libraries were determined with DNA-chip (Bioanalyser 2100 Agilent, 
USA). A normalised concentration of 8 pM of the libraries was loaded on one lane of a High 
Through-put sequencing flowcell (Illumina, USA) to generate the clusters, using a cBot 
(Illumina, USA). The sequencing of the paired-end reads (2 x 50 nucleotides) was done using 
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 an Illumina HiSeq1500 with SBS v3 kits (Illumina, USA). The cluster identification and the 
base calling were done using RTAv1.13 and the quality of the reads was assessed with 
CASAVA v1.8.1 (Illumina, USA). The sequencing resulted in an average of 112 millions of 
reads per sample with, in average, 97% having a quality Phred score greater than 30. The 
quality of the raw sequencing data was assessed using fastx-toolkit (version 0.0.13) 
(http://hannonlab.cshl.edu/fastx_toolkit/index.html) and no pre-processing of the data was 
necessary. The alignment has been done using TopHat2 (version 2.0.11) (Kim et al., 2013) 
against the assembly Zv9 Ensembl 75 of the Danio rerio genome with the parameters -r 180 --
mate-sdt-dev 80 --b2-sensitive --no-novel-junction -a 5 -p 3 --library-type fr-unstranded. The 
raw gene expression was computed using HTSeq (version 0.5.3p3) (Anders et al., 2015) with 
--stranded=no --mode=union parameters. The raw sequencing data (fastq files) and the pre-
processed data (count files) were submitted to the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74754). The normalisation of the 
gene expression and the differential gene expression were both computed using DESeq2 
(Love et al., 2014). At this step, the consistency of the biological replicates was tested using 
hierarchical clustering in a complete mode on Euclidean distances. One control replicate has 
thus been discarded for the rest of the analysis. The significantly differentially expressed (DE) 
genes were selected based on an adjusted p-value of less than 0.05, using the Bonferroni 
multiple testing method. No cut-off was used on the log2 Fold Change. To assess the role of 
GBM subtype markers of the zebrafish tumour model, the name of the 840 GBM subtype 
markers, published by Verhaak et al. (Verhaak et al., 2010), were retrieved from TCGA data 
portal. For the rest of the analysis the markers for GBM subtype were kept but also markers 
not associated to a specific GBM subtype, labelled 'Non type-specific' (Table S3). The 
zebrafish orthologs were then found using the Ensembl database and the BioMart portal 
(Smedley et al., 2015). A curation was applied using 30 % as minimum cut-off for the gene 
sequence identity or 1 as orthology confidence score cut-off. The list of orthologs was then 
manually refined for highly important genes. A total of 1135 zebrafish orthologs were found 
due to the presence of paralogs in the zebrafish genome. The 4 GBM subtypes were similarly 
represented (Figure S5E). To investigate the involvement of markers of a specific GBM 
subtype, the pre-ranked algorithm of Gene Set Enrichment Analysis (GSEA) (Subramanian et 
al., 2005) software package developed by the Broad Institute was used. The significantly DE 
orthologs of the GBM subtype markers were ranked according to their log2 Fold Change and 
then used for enrichment with GSEA for the 4 GBM subtype gene sets. 
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 Analysis of human gene expression data 
Normalised gene expression data (RNAseqV2) of the signature genes for LGG  (n = 530) and 
GBM (n = 166) were downloaded from cBIOPortal (http://www.cbioportal.org/)(Cerami et 
al., 2012) by selecting the studies ids “lgg_tcga” and “gbm_tcga”, respectively. The 
segregation of LGG and GBM samples was tested by Ward’s hierarchical clustering, using (1 
- Pearson’s correlation coefficient) as distance measure. Statistical significance of LGG and 
GBM segregation was estimated by two-sided Fisher Exact test on the two main clusters.  
 
 
IPA analysis 
To predict the effects of gene expression changes in the model QIAGEN’s Ingenuity Pathway 
Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) was applied. The 
complete RNAseq dataset containing the quantitative expression values and corresponding 
adjusted p-values of all genes comparing zebrafish control brain and zebrafish brain tumour 
samples was uploaded to IPA and the cut-off for gene analysis set to 0.05. IPA automatically 
translated zebrafish gene IDs into human gene IDs. For analysis of "Disease or Function" and 
"Upstream Regulator" the default settings from IPA were applied.  
As the RNAseq samples exclusively contained brain tissue the analysis of "Regulatory Effects 
Network" was restricted accordingly by removing liver, kidney, lung, skeletal, cardiac and 
sensory organ effects from the analysis.  
For the analysis of "Network" the default settings from IPA were applied, which restricts the 
outcome to the 25 most significant "Networks". These are constructed between genes of the 
dataset according to the number of known interactions with other genes, assuming that the 
number of interactions correlates with the biological relevance of the gene product. The 
Networks are sorted by "Score" which reflects their interconnectivity. 
 
Western Blot 
Fish were killed by anaesthetic overdose (0.04 % tricaine) and their brains dissected under a 
stereomicroscope. The samples were homogenized in sample buffer (5 % Glycerol, 1.7 % 
SDS, 60 mM TrisHCl pH 6.8, 0.01 % EDTA) containing protease inhibitors (cOmplete, 
Roche, Germany) and phosphatase inhibitors (phosphoStop, Roche, Germany). Equal 
amounts (20-50 mg) of the total extract were separated on 10 % acrylamide gels and 
transferred to a PVDF membrane applying Trans-Blot® TurboTM RTA Transfer Kit, PVDF 
(BioRad, USA) and Trans-Blot® TurboTM Transfer System machine (BioRad, USA). The 
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 membrane was blocked in 2 % BSA and incubated with the following antibodies over night 
(P-Erk (1:200, Cell Signalling, USA, 9101S), YAP (1:200, Cell Signalling, USA, 4912)). 
After washing, the membrane was incubated 1.5 h at RT with horseradish peroxidase-
conjugated goat anti-mouse IgG (Dako, Germany, P0447) or goat anti-rabbit IgG (Dako, 
Germany, P0448), washed again and activated with Pierce® ECL Western Blotting Substrate 
(Thermo Scientific, USA) system. For reuse, the membrane was treated with RestoreTM 
Western Blot Stripping Buffer (Thermo Scientific, USA) according to the supplier’s protocol. 
For normalisation, antibodies against total Erk (1:200, Cell Signalling, 9102) or actin (1:5000, 
Neomarkers-Fremont, USA, ACTN05) were used on stripped membranes.  
 
Cloning 
For the generation of transgenes expressing UAS:BRAFV600E, UAS:Xmrk, UAS:EGFR splice 
variant III (shortened in vIII), UAS:Yap
S5A and UAS:lifeact-GFP we used different strategies. As 
a backbone (vector) we used pT2MUASMCS (a kind gift from Koichi Kawakami), which 
contains a Tol2 based flanking cassette for genomic integration, and five UAS repeats before 
the multiple cloning site. We used conventional cloning of blunt fragments in the EcoRV 
cloning site of the pT2MUASMCS vector, followed by 5’ and 3’ sequencing to check 
orientation and integrity of the insert. Inserts were GFP tagged using gateway recombination 
with pEntry clones of the Tol2kit (Kwan et al., 2007) before being cloned into 
pT2MUASMCS. For UAS controlled myristoylated AKT1 we used gateway recombination to 
clone a 5xUAS:Akt1:5xUAS:BFP construct into pDEST Tol2 CG2.  
The plasmids containing the different oncogenes that were used as templates in Gateway 
cloning were kind gifts of the following labs: BRAFV600E (Liz Patton, Edinburgh, UK); Xmrk 
(Manfred Schartl, Würzburg, Germany), pcDNA3 Myr HA Akt1 was a gift from William 
Sellers (Addgene plasmid # 9008) (Ramaswamy et al., 1999), MSCV-XZ066-EGFRvIII was 
a gift from Alonzo Ross (Addgene plasmid # 20737) (Li et al., 2009), YAPS5A (Sirio Dupont, 
Padova, Italy). Lifeact-GFP (Riedl et al., 2008) was obtained from the authors. 
 
3D visualization 
CLARITY procedure 
Whole-dissected adult brains were fixed in freshly prepared ice-cold methanol-free 
paraformaldehyde (PFA) 4 % (wt/vol) in 0.01 M PBS (pH 7.4) overnight at 4 °C. Samples 
were then infused in a pre-cooled solution of (4 °C) freshly prepared hydrogel monomers 
(0.01 PBS, 0.25 % VA-044 initiator (wt/vol), 5 % dimethyl sulfoxide (vol/vol), 1 % PFA 
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 (wt/vol), 4 % acrylamide (wt/vol) and 0.0025 % bis-acrylamide (wt/vol)) for 2 days at 4 °C. 
After degassing the samples the hydrogel polymerisation was triggered by replacing 
atmospheric oxygen with nitrogen in a desiccation chamber for 3 hours at 37 °C. Samples 
were cleaned from superfluous hydrogel and transferred into embedding cassettes for lipid 
clearing. Passive lipid clearing was performed at 40 °C for 8 days in the clearing solution 
(8 % SDS (wt/vol), 0.2 M boric acid, pH adjusted to 8.5) under gentle agitation. Subsequently 
the samples were thoroughly washed in 0.01 M PBS, tween 0.1 % (wt/vol) (PBSt) at room 
temperature with gentle agitation for 2 days. 
 
Immunostaining of clarified samples 
CLARITY-processed brains were incubated in blocking solution (0.01 M PBS, 0.1 % 
tween 20 (vol/vol), 1 % Triton X100 (vol/vol), 10 % dimethyl sulfoxide (vol/vol), 10 % 
normal goat serum (vol/vol), 0.05 M glycine) overnight at 4 °C. Subsequently samples were 
incubated in staining solution (0.01 M PBS, 0.1 % tween 20 (vol/vol), 0.1 % Triton X100 
(vol/vol), 10 % dimethyl sulfoxide (vol/vol), 2 % normal goat serum (vol/vol), 0.05 % azide 
(vol/vol)) with primary antibody (chicken anti-GFP, Avès Labs, 1:400) for 7 days at room 
temperature under gentle agitation. After four washing steps in PBSt, samples were incubated 
in staining solution with secondary antibody (goat anti-chicken Alexa Fluor 488, Invitrogen, 
1:400) for 7 days at room temperature. Samples were washed for 2 days in PBSt and stained 
with 1 µM DiIC18(3) solution (DiI Stain, Molecular Probes). 
 
Imaging in high refractive index solution 
A fructose-based high refractive index medium (fruM) was prepared as follows: 70 % 
fructose (wt/vol), 20 % DMSO (wt/vol) in 0.002 M PBS, 0.005 % Sodium azide (wt/vol). The 
refractive index of the solution was adjusted to 1.4571 using a refractometer (Kruss).  
In preparation of the imaging the samples were incubated in 50 % (vol/vol) fruM for 6 h and 
finally incubated in fruM for at least 12 h. For imaging, samples were mounted in 1 % 
(wt/vol) low melting point agarose and covered with fruM. Whole-mount brain fluorescence 
was recorded with a Leica TCS SP8 two-photon microscope. Fluorescence was excited using 
a mode locked Ti:Sapphire laser (Chameleon, Coherent) at 770 nm with the Leica HC 
FLUOTAR L 25x/1.00 IMM motCorr objective. Non-descanned detectors with 525/50 and 
585/40 bandpass filters were used for data acquisition. As the specimens are significantly 
bigger than the field of view of the used objective tiled scanning with a voxel size of 
0.9x0.9x1 (µm) or 1.7x1.7x1.7 (µm) was applied. 
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 Image treatment and visualization 
In preparation of the visualisation the image stacks was converted from their native 12 bit lif-
format to series of 8 bit-pngs using CLAHE (Zuiderfeld, 1994) for ImageJ (Schneider et al., 
2012) as implemented in fiji (Schindelin et al., 2012). The implementation is described online 
(Saalfeld, http://fiji.sc/Enhance_Local_Contrast_%28CLAHE%29). The parameters for 
CLAHE were empirically tested and set to a blocksize of 127, 256 bins and a slope of 3 
(default values). While reducing the bit depth from 12 bit to 8 bit fiji's CLAHE plugin 
enhances the contrast and intensity of the weak signals significantly while not over-saturating 
strong signals. By this a significant contrast enhancement and data reduction can be achieved. 
Manual segmentation and 3D rendering was performed with amira (www.fei.com) using a 
combination of the 'Segmentation Editor', 'Voltex', 'Volume Rendering' and 'Surface View' 
modules. 
 
Statistics 
For statistical analysis GraphPad Prism 6 was used applying unpaired Student’s t-tests and 
Bonferroni correction. Values are given in mean ± standard deviation (STD). 
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 Figures 
 
 
 
 
Figure 1: Oncogenic RAS induces proliferation of neural progenitor cells, clonal 
expansion and reduced survival. 
A-B) Schematic representation of tumour induction through (A) the cross between zebrafish 
lines carrying the indicated transgenes or (B) the injection of the oncogenic construct (green) 
into zic:Gal4 embryos to express UAS:GFP-HRASV12 specifically in the brain. C-D) Dorsal 
view of representative 3 dpf images of larvae showing the telencephalon in a control larva (C 
= zic:Gal4, mCherry expression) compared to that of an oncogenic larva (D = zic:RASgermline, 
mCherry expression, D‘ = zic:RASgermline, UAS:GFP-HRASV12 expression), white dotted lines 
mark the eyes. E) Quantification of brain size reveals a doubling in size of the zic:RASgermline 
expressing tissue. F) Counting of BrdU positive cells in the telencephalon of 3 dpf larvae 
reveals doubling in the number of proliferating cells in zic:RASgermline versus zic:Gal4 
controls. G-G‘‘) Dorsal view of three 1 dpf zic:RASsomatic larvae showing individual clones 
expressing UAS:GFP-HRASV12. H-H‘‘‘) Lateral bright field and coronal confocal images of 
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 the telencephalon of three live zic:RASsomatic larvae (plane of focus indicated by red lines in 
H) at 1 dpf, 3 dpf and 5 dpf revealing clonal expansion of oncogene-expressing cells in the 
same larvae from 1 to 5 dpf. I) Survival curve of zic:RASsomatic larvae (green dashed line; 
#=166) compared to zic:Gal4 controls (black line, black asterisk; #=105) and zic:RASgermline 
larvae (green solid line, green asterisk; #=255). Data are represented as mean ± SD. Scale 
bars: C-D = 500 µm; F = 500 µm; F‘ = 50 µm; **p-value<0.03; ***p-value<0.001. 
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Figure 2: Somatic expression of oncogenic RAS induces tumour development and 
heterotopia. 
A-C) Fluorescence images of 2 mpf zebrafish brains of zic:Gal4 (A) and zic:RASsomatic fish 
(B-C) showing (A) a control brain, (B) tumours in the telencephalon ("T"), diencephalon 
("D") and IVth ventricle region ("V") and (C) heterotopia ("H"). D) Graph representing the 
frequency of different lesions due to induction of UAS:GFP-HRASV12 expression (n = 134, of 
which "T" = 83, "D" = 40, "V" = 44, "H" = 67). E-G) Volume rendering of 3D reconstructions 
of two brains with tumours (E-F, green areas) and a brain with heterotopia (G, white arrow) 
shown as dorsal view (inset) and 1 sagittal section (large image). H) 3D reconstruction and 
volume rendering of a brain showing different tumour expansions (colour coded according to 
histological and anatomical features and GFP expression). Scale bars: A-C = 2 mm.  
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Figure 3: Histological and immunological appearance of telencephalic tumour and 
heterotopia. 
A) Representative telencephalic tumour in zic:RASsomatic fish. B) Schematic drawing, 
indicating the position of the sections shown in F-J. C) H&E stained section, boxed area 
indicates enlargement shown in D. E) Summary of the immunohistochemical observations 
related to telencephalic tumours. F-J) Immunostaining of telencephalic tumour sections 
stained as indicated. DAPI as counterstaining is in blue. K) Representative heterotopia in 
zic:RASsomatic fish. L) Schematic drawing, indicating the position of the sections shown in P-
T. M) H&E stained section, boxed area indicates enlargement shown in N. O) Summary of 
the immunohistochemical observations related to heterotopia. P-T) Immunostaining of 
telencephalic tumour sections stained as indicated. DAPI as counterstaining is in blue. Scale 
bars: A, K = 2 mm; C, M = 200 µm; D, F-J, N, P-T = 25 µm. 
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 Figure 4: The zebrafish brain tumours resemble mesenchymal subtypes of human 
GBMs. 
A) Heatmap comparing gene expression data of brains of zic:Gal4 (Control 1-2) and 
zic:RASsomatic fish (Tumour 1-3) representing the normalised expression of the 248 
significantly differentially expressed zebrafish orthologs of human GBM markers (adjusted p-
value<0.05). After row scaling the zebrafish genes visually group into human GBM 
subclasses. B) The Gene Set Enrichment Analysis (GSEA) on the orthologs of the GBM 
human markers shows that only the mesenchymal (MES) subclass is significantly enriched 
(FDR<0.001), associated to 82 zebrafish genes (orthologs of 85 GBM human markers). The 
classical (CL) subclass is associated to 53 zebrafish genes (50 GBM human markers), the 
proneural (PL) subclass to 52 zebrafish genes (51 GBM human markers) and the neural (NL) 
subclass to 27 zebrafish genes (24 GBM human markers). The orange line identifies the 
normalised enrichment score (NES). C) IPA Network analysis suggests a close relation 
between HRAS and YAP in this tumour model as it connects HRAS (network1) with YAP 
(network12) via 4 connections (red lines). 
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Figure 5: A simple YAP signature distinguishes tumours from benign lesions. 
A) Western blot analysis shows increased YAP in tumour versus controls and heterotopia (1 = 
control brain; 2 = heterotopia; 3 = tumour (UAS:GFP-HRASV12germline). B-D) Expression of 8 
YAP-target genes showing upregulation in tumours of the (B) IVth ventricle (n = 6) and (C) 
frontal brain (n = 6) and no upregulation in (D) heterotopia (n = 5) when compared to control 
brains. E) Hierarchical clustering of the gene expression data of the 8-gene YAP signature on 
166 GBM (dark pink) and 530 LGG (light pink) samples using (1 - Pearson's correlation) as 
distance measure. Gene expression is reported as Fragments Per Kilobase of transcript per 
Million fragments mapped (FPKM). 
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Figure 6: YAP activation promotes tumour growth. 
A) Schematic representation of tumour induction through the co-injection of oncogenic 
constructs (green) into zic:Gal4 embryos. B) Quantification of BrdU positive cells in the 
telencephalon of 3 and 14 dpf juveniles reveals doubling in the number of proliferating cells 
in zic:RAS,YAPsomatic fish compared to zic:RASsomatic fish and zic:Gal4 control fish. C) 
Confocal image of 14 dpf fish showing BrdU expression (magenta) in zic:Gal4, zic:RASsomatic 
and zic:RAS,YAPsomatic. D) Survival rate of zic:RASsomatic (green dashed line; #=166) 
compared to zic:Gal4 (black solid line, black asterisk; #=105) and zic:RAS,YAPsomatic (red 
dashed line, red asterisks; #=100). E) Graph representing the frequency of different lesions 
due to zic:RAS,YAPsomatic expression as determined by stereomicroscopic analysis with 
tumours in telencephalon ("T"), diencephalon ("D") and IVth ventricle ("V") and heterotopia 
("H"). F) Immunostaining for GFP, BrdU, GFAP and HU-C of zic:RAS,YAPsomatic fish. Data 
are represented as mean ± SD. Scale bars: C, F = 20 µm; *p-value<0.05; ***p-value<0.001. 
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Disease Models & Mechanisms 9: doi:10.1242/dmm.026500: Supplementary information 
Figure S1: Gal4 expression pattern in control fish (zic:Gal4). 
A-C) Visualisation of zic:Gal4 expression during zebrafish development as indicated. Bright field images (A-
C) and Gal4 expression (A‘-C‘) visualised through mCherry fluorescence at 2 dpf (A), 5 dpf (B) and in the 
brain at 2 mpf (C). Scale bars: A-B = 500 µm, C = 2 mm. 
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Figure S2: Tumours can be induced by different oncogenes. 
A-D) H&E staining of lesions induced by somatic expression of different oncogenes. Boxed area 
indicates enlargement shown in A’-D’, respectively. A’’-D’’) Immunostaining for BrdU of lesions 
induced by somatic expression of different oncogenes. Arrows point at lesions. E) Western blot showing 
the levels of phosphorylated ERK (P-ERK) and actin in control brain (lane 1), heterotopia (lane 2), 
zic:EGFRVIIIsomatic (lane 3), zic:Xmrksomatic (lane 4), zic:AKT-BFPsomatic (lane 5), zic:BRAFE600somatic 
(lane 6), zic:GFP-KRASV12somatic (lane 7) and zic:GFP-HRASV12somatic (land 8). Scale bars: A-C = 100 
µm; D = 1 mm; A’-D’ = 50 µm; A’’-D’’ = 100 µm. 
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Figure  S3 
Figure S3: Histological and immunological appearance of IVth ventricle and diencephalic tumours.  
A) Representative diencephalic tumour in zic:RASsomatic fish. B) Schematic drawing, indicating the 
position of the sections shown in F-J. C) H&E stained section, boxed area indicates enlargement 
shown in D. E) Summary of the immunohistochemical observations related to diencephalic tumours. 
F-J) Immunostaining of heterotopia sections stained as indicated. K) Representative IVth ventricle 
tumour in zic:RASsomatic fish. L) Schematic drawing, indicating the position of the sections shown in 
P-T. M) H&E stained section, boxed area indicates enlargement shown in N. O) Summary of the 
immunohistochemical observations related to IV ventricle tumours. P-T) Immunostaining of IVth 
ventricle tumour sections stained as indicated. Scale bars: A, K= 2 mm; C, M=200 µm; D, F-J, N, P-
T = 25 µm.  
 E   Diencephalic Tumours 
BrdU >15/field 
pERK +++ 
HU-C - 
GFAP +++ 
S100 + 
BrdU/GFP P-Erk HU-C GFAP S100β 
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IVth Ventricle Tumour 
Disease Models & Mechanisms 9: doi:10.1242/dmm.026500: Supplementary information 
A B A‘ B‘ 
Figure S4: Heterotopia occurs also in telencephalon and cerebellum. 
A) Representative telencephalic heterotopia in zic:RASsomatic, boxed area indicates enlargement shown
in A’. B) Representative IVth ventricle heterotopia zic:RASsomatic, boxed area indicates enlargement 
shown in B’. Black arrows point at abnormally localised neural cells (heterotopia). Scale bars: A, B = 
100 µm; A’, B’ = 20 µm.  
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Figure S5: Quality control for zebrafish model RNAseq results. 
A) Dorsal view of stereo images of whole brains from zic:RASsomatic used for RNAseq analysis
(r=rostral, c=caudal). B) Hierarchical clustering of control and tumour samples using Euclidean 
distance on gene expression grouped the samples according to tumour or control. C) The 
volcano plot represents all known zebrafish genes for which a differential expression analysis 
was done. The significantly differentially expressed (DE) genes (adjusted p‑value<0.05) are 
coloured in red (up-regulated) or green (down-regulated). D) After clustering of significantly 
(adjusted p-value<0.05) DE genes based on normalised expression, the genes clustered 
according to regulation, verifying the efficiency of the normalisation step. E) After the 
identification of the zebrafish orthologs of the 840 GBM human markers, through Ensembl 
annotation and manual refinement, more than 80 % of genes could be identified for all four 
GBM subclasses.  
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Figure S6: IPA analysis highlights the oncogenic nature of the model and suggests YAP as a key 
regulator in this tumour model.  
A) The treemap represents IPA results for the disease significantly enriched and belonging to the
superfamily “Cancer”. The color scale fits to the significance (Fisher p-value) and the square size of 
the squares to the number of genes associated to each disease. B) Selection of cancer associated 
pathways determined by IPA to be highly significantly enriched (p-value<2E-06). C) The most 
consistent “Regulator Effects Network”, that IPA generates by linking Upstream Regulators via their 
target genes to physiological effects, contains 6 Upstream Regulators with YAP appearing as the 
most interconnected Upstream Regulator. D) This YAP network has been based on IPA knowledge-
base and more information were gathered through scientific literature. Key players, including YAP 
and TAZ, are found significantly (adjusted p-value<0.05) differentially expressed. The significantly 
upregulated genes are coloured in red and the downregulated genes in green. [1] = Mo et al., 2014; 
[2] = Kodaka et al., 2015; [3] = Anakk et al., 2013; [4] = Lim et al., 2014; [5] = Piccolo et al., 2014 
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Gene	  name	   Log2-­‐Fc	   p-­‐value	  
1.31	   6.30E-­‐06	  yap1	  
ccnd1	  
ctgfa	  
iqgap1	  
itgb2	  
tg:1a	  
tg:r2	  
amot	  
amotl2a	  
amotl2b	  
tp53bp2	  
birc5a	  
wwtr1	  
cyr61	  
hbegfa	  
hbeg:	  
dlg4	  
erbb4a	  
sox2	  
tjp2a	  
ywhag1	  
ywhah	  
1.15	   9.49E-­‐04	  
1.68	   4.41E-­‐22	  
1.95	   1.90E-­‐11	  
1.11	   4.39E-­‐06	  
1.56	   4.85E-­‐05	  
1.15	   5.12E-­‐10	  
1.43	   1.22E-­‐20	  
0.18	   6.13E-­‐01	  
0.44	   4.31E-­‐01	  
0.73	   9.02E-­‐03	  
-­‐0.78	   1.96E-­‐01	  
0.77	   4.20E-­‐03	  
0.47	   5.22E-­‐01	  
2.02	   1.25E-­‐19	  
0.87	   4.53E-­‐02	  
-­‐0.98	   1.95E-­‐16	  
-­‐0.88	   7.92E-­‐09	  
1.05	   2.74E-­‐09	  
-­‐0.69	   2.08E-­‐02	  
-­‐0.63	   3.12E-­‐03	  
-­‐0.51	   7.21E-­‐03	  
A
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
B
Figure S7: YAP signature is enriched in the zebrafish glioma model. 
A) List of YAP related genes with their log2-fold change and p-value determined by RNAseq
analysis of control brains (n=3) and tumours (n=3). B) Fold change of expression of YAP related 
genes determined by qPCR of control brains (n=3) and tumours (n=3). C) Box plots of the gene 
expression of the eigth signature genes in GBM (n = 166) and LGG (n = 530) TCGA samples. 
Reported p-values are estimated by wilcoxon mann whitney (WMW) test. Data are represented as 
mean ± SEM; *pvalue<0.05.  
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Figure S8: Ectopic YAP expression induces brain tumour development. 
A) Schematic representation of tumour induction through the injection of oncogenic constructs
(green) into zic:Gal4 embryos. B) Stereo image of a tumour developed in zic:YAPsomatic. C) YAP 
target gene expression in zic:Gal4 control brains and zic:YAPsomatic tumours. D) Immunostaining for 
BrdU, GFAP and HU-C of zic:YAPsomatic tumours. E) Survival rate of zic:RASsomatic (green dashed 
line) and zic:YAPsomatic (red dotted line) compared to zic:Gal4 (black solid line, black asterix). Data 
are represented as mean ± SD. Scale bars: B = 2 mm; G = 20 µm; *p-value<0.05.  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Disease Models & Mechanisms 9: doi:10.1242/dmm.026500: Supplementary information 
Table S1 
List of oncogenes/transgenes used. 
 
Name of construct Short name References 
UAS:eGFP-HRAS_G12V UAS:GFP-HRASV12 Santoriello et al., 2010 
UAS:Hsa.HIST2H2BE-CFP,Hsa.HRAS_G12V UAS:CFP-HRASV12 Alghisi et al., 2012 
UAS:eGFP-KRAS_G12V UAS:GFP-KRASV12 Park et al., 2014 
UAS:BRAFV600E UAS:BRAFE600 This study 
UAS:Xmrk UAS:Xmrk This study 
UAS:myr-AKT-BFP UAS:AKT-BFP This study 
UAS:eGFP-EGFRvIII UAS:EGFRVIII This study 
UAS:YAPS5A UAS:YAPS5A This study 
UAS:LifeAct-GFP UAS:LA-GFP This study 
 
 
 
 
 
 
Table S2 
List of all brains analized in this study. Oncogene= oncogene used, specifying whether 
through germline or somatic expression; Age = age of fish at the time of brain resection, 
Tel = telencephalic tumour, DD = dorsal diencephalic tumour, IVth ventr = IVth 
ventricular tumour, Het = heterotopia. 
 
Brain 
Oncogene 
(germline) Age [days] 
Image Tel DD IV Ventr 
1 
UAS:GFP-
HRASV12 
69 
 
yes yes yes 
2 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
3 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
4 
UAS:GFP-
HRASV12 
30 
 
yes yes yes 
5 
UAS:GFP-
HRASV12 
30 
 
yes yes yes 
6 
UAS:GFP-
HRASV12 
30 
 
yes yes yes 
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7 
UAS:GFP-
HRASV12 
30 
 
yes yes yes 
8 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
9 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
10 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
11 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
12 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
13 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
14 
UAS:GFP-
HRASV12 
56 
 
yes yes yes 
15 
UAS:GFP-
HRASV12 
59 
 
yes yes yes 
16 
UAS:GFP-
HRASV12 
59 
 
yes yes yes 
17 
UAS:GFP-
HRASV12 
59 
 
yes yes yes 
18 
UAS:GFP-
HRASV12 
59 
 
yes yes yes 
19 
UAS:GFP-
HRASV12 
113 
 
yes yes yes 
20 
UAS:GFP-
HRASV12 
113 
 
yes yes yes 
21 
UAS:GFP-
HRASV12 
113 
 
no yes yes 
22 
UAS:GFP-
HRASV12 
113 
 
yes yes yes 
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23 
UAS:GFP-
HRASV12 
113 
 
yes yes yes 
24 
UAS:GFP-
HRASV12 
113 
 
no yes yes 
25 
UAS:GFP-
HRASV12 
113 
 
yes yes yes 
26 
UAS:GFP-
HRASV12 
73 
 
yes yes yes 
27 
UAS:GFP-
HRASV12 
114 
 
yes yes yes 
28 
UAS:GFP-
HRASV12 
73 
 
yes yes yes 
29 
UAS:GFP-
HRASV12 
114 
 
yes yes yes 
30 
UAS:GFP-
HRASV12 
114 
 
yes yes yes 
31 
UAS:GFP-
HRASV12 
138 
 
yes yes yes 
32 
UAS:GFP-
HRASV12 
224 
 
yes yes yes 
33 
UAS:GFP-
HRASV12 
224 
 
yes yes yes 
34 
UAS:GFP-
HRASV12 
224 
 
yes yes yes 
35 
UAS:GFP-
HRASV12 
227 
 
yes yes yes 
36 
UAS:GFP-
HRASV12 
119 
 
yes yes yes 
37 
UAS:GFP-
HRASV12 
119 
 
yes yes yes 
38 
UAS:GFP-
HRASV12 
119 
 
yes yes yes 
39 
UAS:GFP-
HRASV12 
119 
 
yes yes yes 
40 
UAS:GFP-
HRASV12 
119 
 
yes yes yes 
41 
UAS:GFP-
HRASV12 
175 
 
yes yes yes 
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42 
UAS:GFP-
HRASV12 
175 
 
yes yes yes 
43 
UAS:GFP-
HRASV12 
175 
 
yes yes yes 
44 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
45 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
46 
UAS:GFP-
HRASV12 
94 
 
yes yes yes 
47 
UAS:GFP-
HRASV12 
94 
 
yes yes yes 
48 
UAS:GFP-
HRASV12 
123 
 
yes yes yes 
49 
UAS:GFP-
HRASV12 
123 
 
yes yes yes 
50 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
51 
UAS:GFP-
HRASV12 
39 
 
yes yes yes 
52 
UAS:GFP-
HRASV12 
95 
 
yes yes yes 
53 
UAS:GFP-
HRASV12 
95 
 
yes yes yes 
brain 
Oncogene 
(somatic) 
Age [days] Image Tel DD IV Ventr Het. 
1 UAS:GFP-
HRASV12 
69 
 
no no no yes 
2 UAS:GFP-
HRASV12 
69 
 
yes yes no yes 
3 UAS:GFP-
HRASV12 
62 
 
no no no yes 
4 UAS:GFP-
HRASV12 
62 
 
no no yes yes 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Disease Models & Mechanisms 9: doi:10.1242/dmm.026500: Supplementary information 
5 UAS:GFP-
HRASV12 
75 
 
no no no no 
6 UAS:GFP-
HRASV12 
75 
 
no no no yes 
7 UAS:GFP-
HRASV12 
75 
 
no no no yes 
8 UAS:GFP-
HRASV12 
75 
 
yes no no no 
9 UAS:GFP-
HRASV12 
49 
 
yes yes yes yes 
10 UAS:GFP-
HRASV12 
33 
 
yes yes yes no 
11 
UAS:GFP-
HRASV12 
33 
 
yes no yes no 
12 UAS:GFP-
HRASV12 
33 
 
yes yes no yes 
13 UAS:GFP-
HRASV12 
33 
 
yes no no yes 
14 UAS:GFP-
HRASV12 
33 
 
yes no yes yes 
15 UAS:GFP-
HRASV12 
69 
 
no no no no 
16 UAS:GFP-
HRASV12 
69 
 
no no no no 
17 UAS:GFP-
HRASV12 
69 
 
no no no no 
18 UAS:GFP-
HRASV12 
40 
 
yes yes yes yes 
19 UAS:GFP-
HRASV12 
40 
 
yes no yes no 
20 UAS:GFP-
HRASV12 
40 
 
no no no yes 
21 
UAS:GFP-
HRASV12 
40 
 
yes no yes yes 
22 UAS:GFP-
HRASV12 
40 
 
no no yes yes 
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23 UAS:GFP-
HRASV12 
67 
 
no no no yes 
24 UAS:GFP-
HRASV12 
67 
 
no no no yes 
25 UAS:GFP-
HRASV12 
67 
 
no no no no 
26 UAS:GFP-
HRASV12 
44 
 
yes no no 
no 
 
27 UAS:GFP-
HRASV12 
44 
 
no no no no 
28 UAS:GFP-
HRASV12 
44 
 
no no no yes 
29 UAS:GFP-
HRASV12 
44 
 
yes no no no 
30 UAS:GFP-
HRASV12 
44 
 
yes no no yes 
31 
UAS:GFP-
HRASV12 
44 
 
no no no no 
32 UAS:GFP-
HRASV12 
44 
 
no no no yes 
33 UAS:GFP-
HRASV12 
44 
 
no no no yes 
34 
UAS:GFP-
HRASV12 
44 
 
yes no no no 
35 
UAS:GFP-
HRASV12 
44 
 
no no yes yes 
36 
UAS:GFP-
HRASV12 
44 
 
no no yes no 
37 
UAS:GFP-
HRASV12 
61 
 
yes yes no yes 
38 
UAS:GFP-
HRASV12 
61 
 
yes yes yes yes 
39 
UAS:GFP-
HRASV12 
55 
 
yes yes no no 
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40 
UAS:GFP-
HRASV12 
112 
 
yes yes no yes 
41 
UAS:GFP-
HRASV12 
57 
 
yes no no yes 
42 
UAS:GFP-
HRASV12 
57 
 
yes no yes yes 
43 
UAS:GFP-
HRASV12 
57 
 
yes yes no yes 
44 
UAS:GFP-
HRASV12 
57 
 
yes no yes yes 
45 
UAS:GFP-
HRASV12 
79 
 
yes yes yes yes 
46 
UAS:GFP-
HRASV12 
153 
 
yes no no no 
47 
UAS:GFP-
HRASV12 
128 
 
yes no yes yes 
48 
UAS:GFP-
HRASV12 
128 
 
yes yes yes yes 
49 
UAS:GFP-
HRASV12 
128 
 
yes yes yes yes 
50 
UAS:GFP-
HRASV12 
128 
 
yes yes yes yes 
51 
UAS:GFP-
HRASV12 
128 
 
no no yes yes 
52 
UAS:GFP-
HRASV12 
14 
 
yes yes yes yes 
53 
UAS:GFP-
HRASV12 
14 
 
yes no yes yes 
54 
UAS:GFP-
HRASV12 
26 
 
yes no no no 
55 
UAS:GFP-
HRASV12 
132 
 
yes yes no yes 
56 
UAS:GFP-
HRASV12 
132 
 
no no no yes 
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57 
UAS:GFP-
HRASV12 
135 
 
no no no yes 
58 
UAS:GFP-
HRASV12 
408 
 
yes no no no 
59 
UAS:GFP-
HRASV12 
143 
 
no no no no 
60 
UAS:GFP-
HRASV12 
254 
 
no no no no 
61 
UAS:GFP-
HRASV12 
21 
 
yes no no no 
62 
UAS:GFP-
HRASV12 
61 
 
yes yes no no 
63 
UAS:GFP-
HRASV12 
149 
 
no no no yes 
64 
UAS:GFP-
HRASV12 
90 
 
no no no yes 
65 
UAS:GFP-
HRASV12 
49 
 
yes yes yes no 
66 
UAS:GFP-
HRASV12 
49 
 
yes yes yes no 
67 
UAS:GFP-
HRASV12 
49 
 
yes no yes no 
68 
UAS:GFP-
HRASV12 
179 
 
no no no no 
69 
UAS:GFP-
HRASV12 
179 
 
no no no yes 
70 
UAS:GFP-
HRASV12 
61 
 
yes no yes no 
71 
UAS:GFP-
HRASV12 
61 
 
yes yes no yes 
72 
UAS:GFP-
HRASV12 
61 
 
yes yes no no 
73 
UAS:GFP-
HRASV12 
61 
 
yes yes no no 
74 
UAS:GFP-
HRASV12 
61 
 
yes yes yes yes 
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75 
UAS:GFP-
HRASV12 
111 
 
yes no no no 
76 
UAS:GFP-
HRASV12 
311 
 
no no no no 
77 
UAS:GFP-
HRASV12 
311 
 
no no no no 
78 
UAS:GFP-
HRASV12 
177 
 
yes no yes yes 
79 
UAS:GFP-
HRASV12 
177 
 
yes yes no no 
80 
UAS:GFP-
HRASV12 
70 
 
yes no yes no 
81 
UAS:GFP-
HRASV12 
70 
 
yes yes yes yes 
82 
UAS:GFP-
HRASV12 
440 
 
yes no no yes 
83 
UAS:GFP-
HRASV12 
440 
 
yes no yes no 
84 
UAS:GFP-
HRASV12 
106 
 
yes yes yes yes 
85 
UAS:GFP-
HRASV12 
106 
 
yes no no no 
86 
UAS:GFP-
HRASV12 
106 
 
yes yes no no 
87 
UAS:GFP-
HRASV12 
37 
 
no no no no 
88 
UAS:GFP-
HRASV12 
37 
 
no no no no 
89 
UAS:GFP-
HRASV12 
37 
 
no no no yes 
90 
UAS:GFP-
HRASV12 
37 
 
yes no no no 
91 
UAS:GFP-
HRASV12 
37 
 
yes no yes no 
92 
UAS:GFP-
HRASV12 
37 
 
yes no yes no 
93 
UAS:GFP-
HRASV12 
37 
 
yes no no no 
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94 
UAS:GFP-
HRASV12 
37 
 
yes yes yes no 
95 
UAS:GFP-
HRASV12 
37 
 
yes no yes no 
96 
UAS:GFP-
HRASV12 
37 
 
yes yes yes no 
97 
UAS:GFP-
HRASV12 
37 
 
no no no no 
98 
UAS:GFP-
HRASV12 
37 
 
yes no no no 
99 
UAS:GFP-
HRASV12 
37 
 
no no no no 
100 
UAS:GFP-
HRASV12 
37 
 
no no no no 
101 
UAS:GFP-
HRASV12 
37 
 
no yes yes yes 
102 
UAS:GFP-
HRASV12 
37 
 
no no yes no 
103 
UAS:GFP-
HRASV12 
37 
 
no no no no 
104 
UAS:GFP-
HRASV12 
37 
 
no no no no 
105 
UAS:GFP-
HRASV12 
37 
 
no no no no 
106 
UAS:GFP-
HRASV12 
37 
 
no no no no 
107 
UAS:GFP-
HRASV12 
37 
 
no no no no 
108 
UAS:GFP-
HRASV12 
37 
 
yes yes yes yes 
109 
UAS:GFP-
HRASV12 
37 
 
yes yes no no 
110 
UAS:GFP-
HRASV12 
37 
 
no no no yes 
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111 
UAS:GFP-
HRASV12 
37 
 
no no no no 
112 
UAS:GFP-
HRASV12 
37 
 
yes no no no 
113 
UAS:GFP-
HRASV12 
264 
 
yes yes no no 
114 
UAS:GFP-
HRASV12 
122 
 
yes yes yes yes 
115 
UAS:GFP-
HRASV12 
122 
 
yes yes yes yes 
116 
UAS:GFP-
HRASV12 
122 
 
yes yes yes yes 
117 
UAS:GFP-
HRASV12 
609 
 
yes no no no 
118 
UAS:GFP-
HRASV12 
609 
 
yes no yes no 
119 
UAS:GFP-
HRASV12 
609 
 
yes no no no 
120 
UAS:GFP-
HRASV12 
475 
 
yes no yes yes 
121 
UAS:GFP-
HRASV12 
475 
 
yes no no no 
122 
UAS:GFP-
HRASV12 
145 
 
yes yes no no 
123 
UAS:GFP-
HRASV12 
145 
 
yes yes no yes 
124 
UAS:GFP-
HRASV12 
145 
 
yes no no yes 
125 
UAS:GFP-
HRASV12 
145 
 
yes no no yes 
126 
UAS:GFP-
HRASV12 
145 
 
yes no no no 
127 
UAS:GFP-
HRASV12 
259 
 
yes yes no yes 
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128 
UAS:GFP-
HRASV12 
259 
 
no no yes yes 
129 
UAS:GFP-
HRASV12 
33 
 
yes no no Yes 
130 
UAS:GFP-
HRASV12 
33 
 
yes no yes yes 
131 
UAS:GFP-
HRASV12 
33 
 
no no no yes 
132 
UAS:GFP-
HRASV12 
33 
 
yes no yes yes 
133 
UAS:GFP-
HRASV12 
33 
 
no no no yes 
134 
UAS:GFP-
HRASV12 
33 
 
yes yes no yes 
135 
UAS:GFP-
KRASV12 
25 
 
yes no yes yes 
136 
UAS:GFP-
KRASV12 
25 
 
no no no no 
137 
UAS:GFP-
KRASV12 
25 
 
no no no no 
138 
UAS:GFP-
KRASV12 
25 
 
no no no yes 
139 
UAS:GFP-
KRASV12 
27 
 
no no yes yes 
140 
UAS:GFP-
KRASV12 
27 
 
yes no yes yes 
141 
UAS:GFP-
KRASV12 
27 
 
yes yes yes yes 
142 
UAS:GFP-
KRASV12 
27 
 
no no no no 
143 
UAS:GFP-
KRASV12 
27 
 
no yes no yes 
144 
UAS:GFP-
KRASV12 
27 
 
no no no no 
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145 
UAS:GFP-
KRASV12 
47 
 
yes no yes yes 
146 
UAS:GFP-
KRASV12 
47 
 
yes no yes yes 
147 
UAS:GFP-
KRASV12 
47 
 
yes no yes yes 
148 
UAS:GFP-
KRASV12 
47 
 
yes yes yes no 
149 
UAS:GFP-
KRASV12 
47 
 
yes yes yes no 
150 
UAS:GFP-
KRASV12 
47 
 
no no no no 
151 
UAS:GFP-
KRASV12 
170 
 
no no yes no 
152 
UAS:GFP-
KRASV12 
170 
 
no no no no 
153 
UAS:GFP-
KRASV12 
170 
 
no no no yes 
154 
UAS:GFP-
KRASV12 
170 
 
yes yes yes yes 
155 
UAS:GFP-
KRASV12 
210 
 
no no no no 
156 
UAS:CFP-
HRASV12 
408 
 
no no no yes 
157 
UAS:CFP-
HRASV12 
169 
 
no no no yes 
158 
UAS:CFP-
HRASV12 
169 
 
no no no yes 
159 
UAS:CFP-
HRASV12 
41 
 
no no no yes 
160 
UAS:CFP-
HRASV12 
34 
 
no no yes yes 
161 
UAS:CFP-
HRASV12 
34 
 
no no no yes 
162 
UAS:CFP-
HRASV12 
34 
 
no no no yes 
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163 
UAS:CFP-
HRASV12 
44 
 
no no yes no 
164 
UAS:CFP-
HRASV12 
50 
 
no no yes yes 
165 
UAS:CFP-
HRASV12 
50 
 
no no yes yes 
166 
UAS:CFP-
HRASV12 
50 
 
no no yes yes 
167 
UAS:CFP-
HRASV12 
50 
 
no no yes yes 
168 
UAS:CFP-
HRASV12 
50 
 
no no yes yes 
169 
UAS:CFP-
HRASV12 
50 
 
no yes yes yes 
170 
UAS:CFP-
HRASV12 
50 
 
no yes yes yes 
171 
UAS:CFP-
HRASV12 
48 
 
no no yes no 
172 
UAS:CFP-
HRASV12 
48 
 
no no yes 
yes 
 
173 
UAS:CFP-
HRASV12 
48 
 
no no yes no 
174 
UAS:CFP-
HRASV12 
48 
 
no yes yes yes 
175 
UAS:CFP-
HRASV12 
48 
 
no no no yes 
176 
UAS:CFP-
HRASV12 
48 
 
no no no yes 
177 
UAS:CFP-
HRASV12 
48 
 
no no yes yes 
178 
UAS:CFP-
HRASV12 
48 
 
no no yes no 
179 
UAS:CFP-
HRASV12 
48 
 
yes yes yes yes 
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180 
UAS:CFP-
HRASV12 
48 
 
no no yes yes 
181 
UAS:CFP-
HRASV12 
135 
 
no no yes yes 
182 
UAS:CFP-
HRASV12 
256 
 
no no no no 
183 
UAS:CFP-
HRASV12 
256 
 
no no no yes 
184 
UAS:CFP-
HRASV12 
260 
 
no no yes yes 
185 
UAS:CFP-
HRASV12 
254 
 
no no no no 
186 
UAS:CFP-
HRASV12 
283 
 
no no no no 
187 
UAS:CFP-
HRASV12 
283 
 
no no no yes 
188 
UAS:CFP-
HRASV12 
283 
 
no no no no 
189 
UAS:CFP-
HRASV12 
283 
 
no no no yes 
190 
UAS:CFP-
HRASV12 
283 
 
no no no yes 
191 UAS:EGFRVIII 79 
 
no no no yes 
192 UAS:EGFRVIII 79 
 
no no no no 
193 UAS:EGFRVIII 79 
 
no no no no 
194 UAS:EGFRVIII 79 
 
no no no no 
195 UAS:EGFRVIII 79 
 
no no no no 
196 UAS:EGFRVIII 79 
 
no no no no 
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197 UAS:AKT-BFP 26 
 
no no yes no 
198 UAS:AKT-BFP 62 
 
yes no yes no 
199 UAS:AKT-BFP 62 
 
yes yes yes yes 
200 UAS:AKT-BFP 34 
 
no no yes yes 
201 UAS:AKT-BFP 34 
 
yes no yes yes 
202 UAS:AKT-BFP 42075 
 
no no yes no 
203 UAS:AKT-BFP 42075 
 
no no yes no 
204 UAS:AKT-BFP 42075 
 
no no yes yes 
205 UAS:AKT-BFP 279 
 
no no yes no 
206 UAS:AKT-BFP 340 
 
yes yes yes no 
207 UAS:AKT-BFP 340 
 
no no no no 
208 UAS:AKT-BFP 340 
 
no no no no 
209 UAS:AKT-BFP 340 
 
no no no no 
210 UAS:AKT-BFP 340 
 
no no no no 
211 UAS:AKT-BFP 340 
 
no no no no 
212 UAS:AKT-BFP 320 
 
no no yes no 
213 UAS:AKT-BFP 320 
 
no no yes no 
214 UAS:AKT-BFP 280 
 
no no yes no 
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215 UAS:AKT-BFP 421 
 
no no no yes 
216 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
26 
 
yes yes no no 
217 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
26 
 
yes no no no 
218 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
36 
 
yes yes yes no 
219 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
60 
 
yes no no no 
220 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
60 
 
yes yes no no 
221 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
60 
 
yes yes no no 
222 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
60 
 
yes yes yes no 
223 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
98 
 
no no no no 
224 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
98 
 
yes no no no 
225 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
179 
 
no no no yes 
226 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
179 
 
no no yes no 
227 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
179 
 
yes no no no 
228 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
70 
 
no yes no yes 
229 
UAS:AKT-BFP + 
UAS:GFP-
70 
 
no no no yes 
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HRASV12 
230 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
70 
 
yes yes yes no 
231 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
58 
 
yes no yes no 
232 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
58 
 
yes no no yes 
233 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
58 
 
yes no no no 
234 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
58 
 
yes no no no 
235 
UAS:AKT-BFP + 
UAS:GFP-
HRASV12 
72 
 
yes no yes no 
236 
UAS:BRAFE600 + 
UAS:LA-GFP 
25 
 
no no no no 
237 
UAS:BRAFE600 + 
UAS:LA-GFP 
25 
 
no no no no 
238 
UAS:BRAFE600 + 
UAS:LA-GFP 
25 
 
no no no yes 
239 
UAS:BRAFE600 + 
UAS:LA-GFP 
25 
 
no no yes no 
240 
UAS:BRAFE600 + 
UAS:LA-GFP 
25 
 
no no no no 
241 
UAS:BRAFE600 + 
UAS:LA-GFP 
25 
 
no no yes yes 
242 
UAS:BRAFE600 + 
UAS:LA-GFP 
25 
 
no no no 
yes 
 
243 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
no no no yes 
244 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
no no no no 
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245 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
no yes no yes 
246 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
no no no yes 
247 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
no no yes yes 
248 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
no yes yes yes 
249 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
no yes yes yes 
250 
UAS:BRAFE600 + 
UAS:LA-GFP 
85 
 
yes no no yes 
251 
UAS:Xmrk + 
UAS:GFP 
27 
 
yes no no no 
252 
UAS:Xmrk + 
UAS:GFP 
27 
 
no no yes no 
253 
UAS:Xmrk + 
UAS:GFP 
27 
 
no no no yes 
254 
UAS:Xmrk + 
UAS:GFP 
27 
 
yes no yes no 
255 
UAS:Xmrk + 
UAS:GFP 
27 
 
yes no yes yes 
256 
UAS:Xmrk + 
UAS:GFP 
77 
 
no no no no 
257 
UAS:Xmrk + 
UAS:GFP 
77 
 
no no yes 
no 
 
258 
UAS:Xmrk + 
UAS:GFP 
77 
 
yes no no no 
259 
UAS:Xmrk + 
UAS:GFP 
77 
 
no no no no 
260 
UAS:GFP-
HRASV12 + 
UAS:YapS5A 
39 
 
yes no no no 
261 
UAS:GFP-
HRASV12 + 
UAS:YapS5A 
39 
 
yes no yes yes 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Disease Models & Mechanisms 9: doi:10.1242/dmm.026500: Supplementary information 
262 
UAS:GFP-
HRASV12 + 
UAS:YapS5A 
21 
 
yes yes no no 
263 
UAS:GFP-
HRASV12 + 
UAS:YapS5A 
22 
 
yes yes no no 
264 
UAS:GFP-
HRASV12 + 
UAS:YapS5A 
23 
 
no yes yes no 
265 
UAS:GFP-
HRASV12 + 
UAS:YapS5A 
40 
 
no yes no no 
266 
UAS:GFP-
HRASV12 + 
UAS:YapS5A 
40 
 
yes no yes no 
267 UAS:GFP-
HRASV12 + 
UAS:YapS5A 
40 
 
yes yes yes no 
268 UAS:YapS5A 47 
 
yes no yes 
269 UAS:YapS5A 54 
 
yes yes no 
270 UAS:YapS5A 54 
 
yes yes no 
271 UAS:YapS5A 54 
 
no yes no 
272 UAS:YapS5A 54 
 
no yes no 
273 UAS:YapS5A 54 
 
no yes no 
274 UAS:YapS5A 54 
 
no yes no 
275 UAS:YapS5A 54 
 
no yes no 
276 UAS:YapS5A 88 
 
no yes yes 
277 UAS:YapS5A 88 
 
no no no 
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278 UAS:YapS5A 88 
 
yes yes no 
279 UAS:YapS5A 88 
 
yes yes yes 
280 UAS:YapS5A 88 
 
yes no yes 
281 UAS:YapS5A 88 
 
yes yes yes 
282 UAS:YapS5A 76 
 
no yes no 
283 UAS:YapS5A 76 
 
no yes yes 
284 UAS:YapS5A 76 
 
yes yes yes 
285 UAS:YapS5A 76 
 
yes yes no 
286 UAS:YapS5A 76 
 
yes yes no 
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Click here to Download Table S3 
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Table S4 
List of YAP-related genes. 
 
Ensemble Gene ID log2(Fold Change) adjusted pvalue Gene Name 
ENSDARG00000003293 1,571224817 2.42960518357847e-14 sox9a 
ENSDARG00000005560 -0,510306743 0,007207761 ywhah 
ENSDARG00000013078 -0,294928053 0,022141049 ywhaba 
ENSDARG00000013207 0,574374872 0,002604248 zeb1b 
ENSDARG00000016939 1,107244515 4.38714229014954e-06 itgb2 
ENSDARG00000017953 1,070160674 0,078005579 tp73 
ENSDARG00000023062 -0,626818162 0,137369882 cyr61 
ENSDARG00000031246 0,870149527 0,045303211 hbegfb 
ENSDARG00000031888 -0,448720304 0,008131336 mapk8a 
ENSDARG00000034541 1,145555547 5.11709946291477e-10 tgfbr2 
ENSDARG00000035873 2,029999584 8.72337651152246e-17 FJX1 
ENSDARG00000040046 -0,587421331 0,318125688 snai2 
ENSDARG00000041502 1,556557578 4.85106282821561e-05 tgfb1a 
ENSDARG00000042518 0,174017463 0,342168185 hipk2 
ENSDARG00000042934 1,684581537 4.4061432941375e-22 ctgfa 
ENSDARG00000045482 -0,26735682 0,305865584 stk38l 
ENSDARG00000046074 -0,245678658 0,424381998 stk11 
ENSDARG00000052960 0,016107369 0,986059128 nppa 
ENSDARG00000059483 0,713050005 0,01293987 tead1b 
ENSDARG00000060010 0,834518645 0,002447814 iqgap2 
ENSDARG00000063207 -0,877140352 7.92317473034202e-09 erbb4a 
ENSDARG00000063309 -0,691094485 0,020763688 tjp2a 
ENSDARG00000067626 -0,631573182 0,003117126 ywhag1 
ENSDARG00000067719 0,769116894 0,004197799 wwtr1 
ENSDARG00000068401 1,307768588 6.29935735788389e-06 yap1 
ENSDARG00000070913 1,049586262 2.74457242921734e-09 sox2 
ENSDARG00000075121 2,019581157 1.24955028420221e-19 hbegfa 
ENSDARG00000075621 -0,784354196 0,195987459 birc5a 
ENSDARG00000078335 1,431974201 1.2233826686997e-20 amot 
ENSDARG00000078864 0,118871538 0,596309583 lats2 
ENSDARG00000078888 1,949154437 1.89557208991909e-11 iqgap1 
ENSDARG00000089536 -0,388858143 0,163063104 erbb4b 
ENSDARG00000092260 -0,538246207 0,000125477 WBP1 
ENSDARG00000026531 -0,246570951 0,215356428 alcama 
ENSDARG00000058538 -0,557665776 NA alcamb 
ENSDARG00000061923 0,177676238 0,613424671 amotl2a 
ENSDARG00000061948 0,439090942 0,430753957 amotl2b 
ENSDARG00000063649 0,619532181 0,057323825 tead3b 
ENSDARG00000074321 -0,121994384 0,874302367 tead3a 
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Table S5 
 
 
 
Click here to Download Table S5 
 
 
 
 
 
 
Table S6 
 
 
 
Click here to Download Table S6 
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